Abstract
DNA Damage Response (DDR) factors Ataxia Telangiectasia Mutated (ATM) and p53 Binding Protein 1 (53BP1) function as tumor suppressors in humans and mice, but the significance of their mutual interaction to the suppression of oncogenic translocations in vivo has not been investigated. To address this question, we have examined here phenotypes of mice lacking 53BP1 and ATM (Trp53bp1−/−/Atm−/−), relative to single mutants. These analyses reveal that loss of 53BP1 markedly decreases the latency of T lineage lymphomas driven by RAG-dependent oncogenic translocations in Atm−/− mice (average survival, 23 and 14 weeks for Atm−/− and Trp53bp1−/−/Atm−/− mice, respectively). Mechanistically, 53BP1 deficiency aggravates the deleterious effect of ATM deficiency on nonhomologous end-joining (NHEJ)-mediated double-strand break (DSB) repair. Analysis of V(D)J recombinase-mediated coding joints (CJs) and signal joints (SJs) in Trp53bp1−/−/Atm−/− primary thymocytes is, however, consistent with canonical NHEJ-mediated repair. Together, these findings indicate that the greater NHEJ defect in double mutants results from a decrease in the efficiency of rejoining rather than a switch to alternative NHEJ-mediated repair. Complementary analyses of irradiated primary cells indicate that defects in cell cycle checkpoints subsequently function to amplify the NHEJ defect, resulting in more frequent chromosomal breaks and translocations in double mutants cells throughout the cell cycle. Finally, we find that 53BP1 is dispensable for the formation of RAG-mediated hybrid joints (HJs) in Atm−/− thymocytes, but is required to suppress large deletions in a subset of HJs. Collectively, these results uncover novel ATM-independent functions for 53BP1 in the suppression of oncogenic translocations and in radioprotection.
Keywords: 53BP1, ATM, lymphoma, translocation, double-strand break
Introduction
In response to DNA double-strand breaks (DSBs), mammalian cells have evolved the DNA Damage Response (DDR), a set of ubiquitous factors responsible for their detection, signaling and repair (1, 2). Upon DSB induction, the Ataxia Telangiectasia Mutated (ATM) kinase phosphorylates hundreds of substrates to promote cell cycle checkpoint activation and repair via either nonhomologous end-joining (NHEJ) or homologous recombination (HR) (3). In this context, ATM phosphorylates MDC1 to promote chromatin ubiquitination, an essential step for the recruitment of the 53BP1 adaptor to specific histone marks at sites of DSBs (4). 53BP1 in turn facilitates nonhomologous end-joining (NHEJ)-mediated repair via several mechanisms (reviewed in (5)), such as protecting broken ends from extensive end-resection (6, 7) and, in some cellular contexts, regulation of higher-order chromatin reorganization (8, 9).
Activation of the DDR represents a key barrier to cancer development (10) and, accordingly, ATM and 53BP1 are tumor suppressors in humans. Individuals with the hereditary disease Ataxia-Telangiectasia (A-T; lacking ATM) are markedly cancer prone (11). Moreover, acquired ATM mutations are frequent in B cell malignancies, where they correlate with aggressive disease and poor clinical outcome (12). Similarly, diminished 53BP1 expression is observed in lymphomas as well as solid tumors (13–17). Moreover, low levels of 53BP1 often correlate with aggressive disease (13–17) and may represent a main mechanism for acquisition of resistance to therapy in breast cancers (18).
Previous studies indicate that 53BP1 functions to concentrate activated ATM and other repair factors at sites of DSBs (19, 20). In turn, ATM-dependent phosphorylation of the 53BP1 amino terminus is essential for recruitment of Rif1 (21–24), the downstream mediator of 53BP1 in the suppression of end-resection (21–25). However, little is known on how these molecular interactions modulate the formation of chromosomal translocations in vivo, particularly in the context of oncogenic stress. Here, we address this question via analysis of newly generated compound mutant mice (Trp53bp1−/−/Atm−/− mice).
Materials and Methods
Mice and cells
Trp53bp1−/− mice (26) and Atm−/− mice (27) were obtained from Drs. Junjie Chen and Fred Alt, respectively. Trp53bp1−/− mice were backcrossed into 129/Sv mice for six generations and then bred to 129/Sv Atm−/− mice to generate double mutants and all corresponding controls. All mouse experiments were conducted in accordance with Institutional Animal Care and Use Committee (IACUC)-approved protocols and following guidelines from the US Public Health Policy on Humane Care and Use of Laboratory Animals. Purification and in vitro activation of mature B and T lymphocytes was done as described (28). For irradiation experiments, mice or cells were exposed to 2 Gy of IR using a 137Cs source (GammaCell40), at a rate of 0.5 Gy/min.
Immunophenotyping and cell cycle analysis
Thymocytes and splenocytes of 8–12 week-old mice were stained with antibodies to T cell or B cell markers, as described (28). For quantification of the mitotic population, cells were co-stained with an α-phospho-histone H3 (Ser10) antibody (Millipore) and propidium ioidide (PI). Data was acquired using a FACSCalibur and analyzed with FlowJo software.
Cytogenetic assays
Metaphase preparation and telomere FISH were previously described (28). For TCRα/δ locus-specific FISH, we detected the 5′ end of the locus using BAC RP23-304L21 (purchased from Children’s Hospital Oakland Research Institute) and the 3′end using BAC TCR-Cα (kind gift of Dr. Carol Greider). BAC labeling, hybridization and detection were performed as described (28). Paints to mouse chromosomes 12 and 14 were purchased from Cambio (Cambridge, England) and hybridized following manufacturer’s instructions. All images were acquired using a Zeiss Axioplan Imager Z.1 microscope equipped with a Zeiss AxioCam and an HXP120 mercury lamp (Jena GmbH) and dedicated software (Zeiss Axiovision Rel 4.6) (28). Spectral Karyotyping analysis was done as described (29).
Histopathology, immunohistochemistry and TUNEL assay on mouse tissues
Five-micron sections from formalin-fixed paraffin-embedded mouse organs were stained with hematoxylin and eosin (H/E) and evaluated by a veterinary pathologist (DLH). Immunostaining and detection of TUNEL+ cells were done as previously described (29).
Immunoblotting
Cells were resuspended in RIPA buffer and protein transferred to PVDF membranes as described (29). Antibodies used were: p53 (Cell Signaling #; 1:1000); phospho-p53 (Ser15) (Cell Signaling #; 1:1000); KAP-1 (#; 1:1000); phospho-KAP1 (Bethyl Laboratories, 1:5000), or α-tubulin (Millipore, 1:5000).
Real time quantitative PCR (RT-PCR)
Thymocytes were resuspended in Trizol and RNA extracted following manufacturer’s protocols. Two μg of RNA were reverse transcribed using RT-III (Invitrogen) and cDNA was amplified using Power Sybr® Green PCR Master Mix in a 7900HT Fast Real-Time PCR System with SDS v2.3 software. Data was analyzed using RQ Manager v1.2, all from Applied Biosystems (Carlsbad, California). Primers were: p21-F: 5′-TCCACAGCGATATCCAGACATT-3′; p21-R: 5′-ACGCGCTCCCAGACGAAGTTG-3′; Bax-F: 5′-CAGGATGCGTCCACCAAGAA-3′; Bax-R: 5′-CGTGTCCACGTCAGCAATCA-3′, Gapdh-F: 5′-CATGGCCTTCCGTGTTCCTA-3′; Gapdh-R: 5′-TGCCTGCTTCACCACCTTCT-3′.
Indirect immunofluorescence on cells and tissue cryosections
Splenocyte cytospins or 5-μm thymus cryosections were fixed in 4% paraformaldehyde (PFA) and immunofluorescence for γ-H2AX was done as described (28).
Sequencing of coding joints (CJs) and signal joints (SJs)
All analyses were done on thymus genomic DNA from 7 day-old mice. PCR, cloning, and sequencing of the Vδ5-Dδ2 SJ was performed as described (30). PCR, cloning and sequencing of the Vδ2-Jδ1 CJ was done as for the SJ analysis, using published primers (8).
Hybrid joint (HJ) analysis
For Dβ2-Vβ14 HJ analysis, the joint was first amplified using previously described primers (31) or newly designed primers equidistant from the junction. For the latter experiments, the primary reaction primers were: TCR5′Dβ2 Mus: GTGCACTCCAGAGAGTGCTCATGC and TCR 3′Vβ14 Mus: CTAGACAAAGACCATCTTGAACTATGC, with an annealing temperature of 56.8°C for 20 cycles. The secondary reaction primers were: TCR 5′Dβ2 Mus inside: GCACAGACAACAAGACAGGATGC and TCR 3′Vβ14 Mus inside: CCTTTCTCCTGGGCATGTTCTTG, with an annealing temperature of 57.4°C for 30 cycles. A portion of the Rag1 locus was amplified from the genomic templates as a loading control, as described (30). Dβ2-Vβ14 HJ PCR products were transferred to a nylon membrane and hybridized overnight with a 32P-labeled probe that recognizes sequences in the 5′ portion of Vβ14. Specific amplicons representing HJs harboring deletions were cut from the gel, purified, cloned into TOPO-pCR2.1 (Invitrogen) and sequenced.
Statistical analysis
We evaluated significance using Student’s t-test on 3–5 datapoints per genotype. For analysis of survival, we used the log rank test.
Results
Trp53bp1−/−/Atm−/− mice are viable and show no additional phenotypes in growth and development relative to Atm−/− mice
Intercrosses of Trp53bp1+/−/Atm+/− mice produced Trp53bp1−/−/Atm−/− mice at approximately Mendelian ratios (10/102 mice; expected=6.4; Table S1). Like Atm−/− and, to a lesser extent, Trp53bp1−/− mice, double mutants are growth retarded (Fig. S1A–B). However, the effect of the combined deficiency on growth was not additive, but comparable to the defect in Atm−/− mice (Fig. S1A–B). Similarly, the decreased cellularity and relative paucity of mature T cells observed in Atm−/− thymi and spleens were not further aggravated by concomitant 53BP1 deficiency (Fig. S1C–H). Pathology of Trp53bp1−/−/Atm−/− organs revealed severe ovarian/testicular atrophy (comparable to Atm−/− mice; Fig. S1I and data not shown) and no significant alterations in the brain (not shown). Altogether, these findings suggest that 53BP1 and ATM function in mostly overlapping pathways during growth and development.
53BP1 deficiency accelerates lymphomagenesis in Atm−/− mice
Organismal development is mostly impaired in the context of deficiencies for Homologous Recombination (HR), a pathway that is dependent on ATM but not 53BP1 (28, 32). We therefore sought to investigate nonoverlapping roles for ATM and 53BP1 in a NHEJ-dependent process: V(D)J recombination in developing thymocytes. Here, Recombination Activating Gene (RAG) introduces DSBs within antigen receptor loci in the G1 phase of the cell cycle and NHEJ repairs them prior to DNA synthesis (30). In Atm−/− thymocytes, defective NHEJ leads to their aberrant rejoining to DSBs elsewhere to form chromosomal translocations (31, 33). Over time, selection for oncogenic translocations drives lymphomagenesis (33). To assess the effect of 53BP1 deficiency on this process, we first examined lymphoma proneness of Trp53bp1−/−/Atm−/− and Trp53bp1+/−/Atm−/− mice, relative to Atm−/− controls. Consistent with previous findings (27), 18/39 (46.1%) Atm−/− mice had succumbed at 6 months of age. Significantly, 35/38 (92.1%) Trp53bp1−/−/Atm−/− mice had died at the same timepoint. Overall, average survival was 23 and 14 weeks for Atm−/− and Trp53bp1−/−/Atm−/− mice, respectively (Fig. 1A; p=0.0001). In addition, 37/37 (100%) Trp53bp1−/−/Atm−/− necropsies but only 27/32 (84.3%) Atm−/− necropsies revealed thymic lymphoma as the cause of death. Frequent tumor infiltrates were present in all major organs of Trp53bp1−/−/Atm−/− mice at the time of death (Fig. 1B). We conclude that loss of 53BP1 markedly decreases the latency and increases the penetrance of thymic lymphomagenesis in Atm−/− mice. In contrast, the average survival of Trp53bp1+/−/Atm−/− was comparable to Atm−/− mutants (25 weeks; Fig. 1A), indicating that one copy of 53BP1 is sufficient to suppress lymphomagenesis in this setting.
Atm−/− lymphomas originate from thymic precursors undergoing V(D)J recombination and invariably harbor clonal translocations with a breakpoint at the TCRα/δ locus in chromosome 14 (33) and amplification of upstream sequences (34). Similarly, Trp53bp1−/−/Atm−/− lymphoblasts were typically double positive (CD4+/CD8+) or, less frequently, single positive (CD4+ or CD8+) (Table 1; Fig. 1C), lacked significant aneuploidy (Table 1, Fig. S2) and 6/6 tumors contained a clonal translocation involving chromosome 14, with 4/6 harboring a t(12,14) in over 90% of metaphases (Table 1; Fig. 1D). Moreover, hybridization with BAC probes that recognize sequences over the Cα region or immediately centromeric to the Vα region revealed “split” BAC signals and marked amplification of sequences 5′ to the TCRα/δ locus in most lymphoma cells (n=6 tumors; Fig. 1E–G; Fig. S3 for additional examples). More limited analyses by Spectral Karyotyping (SKY) confirmed these findings and revealed other co-existing clonal translocations (see Fig. S4), in line with previous analyses of Atm−/− lymphomas (33). Altogether, these findings suggest that loss of 53BP1 promotes lymphomagenesis in Atm−/− mice by accelerating the rate of formation of oncogenic translocations involving the TCRα/δ locus and possibly other loci.
Table 1.
Mouse ID | Genotype | Gender | Age at death (weeks) | Tumor CD4/CD8 labelinga | Chromosome paint analysis
|
# chromosomes/ cell (range) b | |
---|---|---|---|---|---|---|---|
chrom 14 abnormalities (% metaphases) | chrom 12 abnormalities (% metaphases) | ||||||
M#4 | Atm−/− | F | 16.5 | DP | n.d. | n.d. | n.d. |
M#36 | Atm−/− | F | 16 | CD4 SP | n.d. | n.d. | n.d. |
M#30 | Atm−/− | F | 23 | DP | Yes (98%) | Yes (98%) | 41.7 ± 0.5 (41–42) |
M#35 | Atm−/− | M | 24 | DP | Yes (100%) | Yes (100%) | 40.0 ± 0.0 (40-40) |
| |||||||
M#2 | Trp53bp1+/−/Atm−/− | M | 12 | DP | n.d. | n.d. | n.d. |
M#5 | Trp53bp1+/−/Atm−/− | F | 18 | DP/DN | n.d. | n.d. | n.d. |
M#49 | Trp53bp1+/−/Atm−/− | M | 12 | DP/CD4 SP | n.d. | n.d. | n.d. |
M#10 | Trp53bp1+/−/Atm−/− | F | 27 | DP/CD4 SP | n.d. | n.d. | n.d. |
M#70 | Trp53bp1+/−/Atm−/− | M | 14 | DP | n.d. | n.d. | n.d. |
| |||||||
M#11 | Trp53bp1−/−/Atm−/− | M | 14.5 | DP | Yes (96%) | Yes (98%) | 39.8 ± 0.4 (39–40) |
M#16 | Trp53bp1−/−/Atm−/− | M | 15 | CD4 SP | Yes (96%) | No | 41.7 ± 103 (38–44) |
M#21 | Trp53bp1−/−/Atm−/− | M | 16.5 | DP | Yes (100%) | Yes (100%) | 40.8 ± 0.6 (40–42) |
M#28 | Trp53bp1−/−/Atm−/− | M | 16 | DP | Yes (98%) | Yes (94%) | 40.1 ± 0.6 (39–41) |
M#37 | Trp53bp1−/−/Atm−/− | M | 14 | DP | Yes (100%) | Yes (100%) | 40.0 ± 0.5 (39–41) |
M#39 | Trp53bp1−/−/Atm−/− | M | 13.5 | DP/CD8 SP | Yes (92%) | Yes (92%) | 40.0 ± 0.2 (40–41) |
DP, double positive for CD4 and CD8; SP, single positive; mixed populations were observed in some tumors, as indicated.
average and standard deviation; n=20–30 metaphases per tumor; n.d., not done.
Loss of 53BP1 aggravates the defect in canonical NHEJ in Atm−/− cells
Because NHEJ normally suppresses RAG-dependent translocations, the findings above strongly suggested a greater defect in NHEJ in double mutants. To evaluate this pathway in more detail, we took advantage of the fact that murine splenocytes are mostly noncycling and therefore rely on NHEJ for DSB repair. To assess the kinetics of NHEJ-mediated repair, resting wt, Trp53bp1−/−, Atm−/− and Trp53bp1−/−/Atm−/− splenocytes were irradiated and the number of γ-H2AX foci, that mark sites of DSBs, quantified over time. At 1 hour after IR, the number of foci was comparable across genotypes (Fig. 2A–B and data not shown), validating the use of this assay in our backgrounds. At later time-points however we observed a delay in the resolution of γ-H2AX foci in double mutants relative to Atm−/− controls, suggesting delayed DSB repair (Fig. 2A–B; n=2 independent experiments). These differences did not reflect on increased radioresistance of double mutant cells, because the viability of Trp53bp1−/−/Atm−/− and Atm−/− irradiated cells was similar and, as expected, markedly increased relative to wt or Trp53bp1−/− cells (Fig. S5).
To further examine this question in a cell type more relevant to our tumor model and bypass potential artifacts associated with cell culture, we also quantified IR-induced γ-H2AX foci in thymus cryosections after allowing for in vivo repair (Fig. 2C). Foci analysis was done on the thymic cortex, which consists mostly of nondividing lymphocytes. Consistent with our observations in B cells, the number of γ-H2AX foci per nucleus was increased in irradiated double mutant thymocytes relative to Atm−/− controls, particularly 24 hours after IR (Fig. 2C). Altogether, these experiments indicate that loss of 53BP1 delays NHEJ-dependent repair in ATM-deficient cells in pre-replicative phases of the cell cycle, suggesting a mechanism for accelerated formation of RAG-dependent translocations.
53BP1 is thought to promote canonical, ligase IV-dependent NHEJ by providing a chromatin context that suppresses inappropriate end-resection, a molecular event that triggers alternative, error-prone end-joining (A-NHEJ) (6, 35). In the context of RAG-mediated DSBs, end-resection results in sequence alterations that can be readily identified by examining specific joints. However, sequences at two endogenous recombination junctions (the Vδ2-Jδ1 CJ (Fig. S6) and the Vδ5-Dδ2 SJ (Fig. S7)), in Trp53bp1−/−/Atm−/− mice were indistinguishable from wt, suggesting that canonical ligase IV-dependent NHEJ remains the predominant pathway in double mutants (see Fig. S8 for the distribution of deletion size at coding and signal ends across genotypes). Specifically, we did not observe an increase in the frequency of microhomologies (MH), a footprint of alternative NHEJ (35), nor did we observe templated additions associated with products of mistimed V(D)J recombination (30) or with some oncogenic chromosomal translocations (36). We noted only rare deletions, consistent with previous observations in 53BP1-deficient cells (8).
Severe defect in p53 activation in Trp53bp1−/−/Atm−/− thymocytes
In lymphoid cells, unrepaired DSBs in G1 elicit p53 activation to regulate the G1/S checkpoint and growth arrest/apoptosis. p53 activation is severely compromised in Atm−/− primary thymocytes, allowing for replication of G1-induced DSBs (37). To investigate an effect of 53BP1 deficiency on the ATM/p53 axis, we monitored IR-induced p53 stabilization and effector functions in double mutant and control thymocytes (Fig. 3). As expected, IR-induced p53 stabilization and phospho-p53 (Ser15) formation were robust in irradiated wt and Trp53bp1−/− cells, but markedly attenuated in Atm−/− thymocytes (Fig. 3A–B). A similar defect was observed in double mutants, regardless of whether radiation was administered in vitro (Fig. 3A) or in vivo (Fig. 3B). IR-dependent phosphorylation of KAP-1, another posttranslational modification primarily dependent on ATM, was also compromised to a comparable extent in Atm−/− and Trp53bp1−/−/Atm−/− cells (Fig. 3A–B). As for Atm−/− cells (38), residual p53 activation and KAP-1 phosphorylation in double mutants was dependent on DNA-PKcs, because it was abrogated by pretreatment with the DNA-PKcs inhibitor NU7026 (Fig. 3C). Finally, IR-induced transcriptional activation of two main p53 targets, p21 and Bax, and thymocyte apoptosis were also attenuated to a similar extent in Atm−/− and Trp53bp1−/−/Atm−/− cells (Fig. 3D–F). Collectively, these experiments indicate that double mutant cells show a severe defect in p53 activation, providing a mechanism for amplification of their increased NHEJ defect.
53BP1 is dispensable for ATM-dependent repair of replication-associated DSBs
In addition to regulating the repair of pre-replicative DSBs, ATM promotes the signaling and repair of replicative DSBs. To assess an effect of 53BP1 in this context, we next examined the kinetics of DSB repair in mature in vitro activated B cells (Fig. 4). We previously showed that B cell activation with α-CD40/IL-4 counteracts p53 activation in response to spontaneous DSBs (39). Consistent with those findings and a recent report (23), activated wt B cells exposed to IR (2 Gy) did not undergo significant G1/S arrest or apoptosis, but rather a transient arrest in G2 (Fig. S9). This was determined by the accumulation of cells with 4N DNA content that were also negative for the mitotic marker phospho-H3 (Ser10). In wt cells, the G2 arrest peaked by 6 hours post-IR and was resolved by 24 hours post-IR (Fig. S9). In contrast, all single and double mutants showed persistent arrest at 24 hours (n=5 independent experiments; Fig. 4A–B; Fig. S9). Significantly, double mutants consistently showed further delayed cell cycle kinetics relative to Atm−/− cells (Fig. 4A–B; Fig. S9), correlating with increased number of γ-H2AX foci at the same time-points (Fig. 4C–D). Finally, these analyses revealed that, upon irradiation, a subset of Trp53bp1−/−/Atm−/− and, to a lesser extent, Atm−/− and Trp53bp1−/− activated B cells undergo a second round of inappropriate synthesis, resulting in the formation of tetraploid (8N) cells (Fig. 4E–F). The greater frequency of cells with DNA content greater than 4N in double mutants is consistent with their greater load of DSBs (Fig. 4C–D) and suggests an additional mechanism for increased genomic instability (40).
The increased load of DSBs in G2 likely result from “carry-over” of G1 breaks as well as deficient repair of newly introduced DSBs during replication. To determine whether 53BP1 may also modulate genomic instability associated with replication in Atm−/− cells, we examined genomic stability in metaphase spreads of activated B cells treated with the PARP inhibitor olaparib (Fig. S10). As expected (41), olaparib induced frequent chromatid breaks in α-CD40/IL-4-activated Atm−/− cells. 53BP1 status had no measurable effect on this phenotype, suggesting that 53BP1 aggravates DSB repair in ATM-deficient cells specifically in the context of NHEJ. These findings are consistent with our previous observations that mice lacking 53BP1 and PARP1 lack additional phenotypes (28). In further support of this notion, the frequency of hydroxyurea (HU)-induced DSBs was also comparable in Atm−/− and Trp53bp1−/−/Atm−/− cells (Table S2).
53BP1 suppresses chromosomal translocations in primary Atm−/− cells
To test the effect of persistent DSBs on translocation formation, we next quantified breaks and translocations in mitotic chromosomes of activated B cells. As expected (42), we observed an increased frequency of both spontaneous and IR-induced aberrations in all DNA repair-deficient mutants relative to wt controls (n=6 independent experiments; Fig. 4G–I, Table S3 for summary, Table S4 for individual experiments). Consistent with the lack of additional organismal phenotypes in growth and development (Fig. S1), the frequency of spontaneous breaks was similar in Atm−/− and Trp53bp1−/−/Atm−/− B cells (Fig. 4G “mock”). In contrast, IR consistently induced an “excess” of chromosomal aberrations in Trp53bp1−/−/Atm−/− cells relative to Atm−/− controls (n=6 independent experiments; n=0.5–3.2 “excess” breaks per cell (Fig. 4G “2 Gy”). When normalized to the Atm−/− control in the same stimulation, this difference was highly significant (p=0.009; Fig. 4H). The “excess” breaks were mostly “chromosome-type” (centrics and acentrics), consistent with their origin prior to replication (Fig. 4I). These observations were not specific to these experimental conditions, because we similarly observed an increase in the frequency of IR-induced aberrations in LPS-activated B cells (3.7 and 4.4 breaks/metaphase for Atm−/− and Trp53bp1−/−/Atm−/− cells, respectively; Table S5) or in concanavalin A-activated T cells (3.0 and 3.4 breaks/metaphase for Atm−/− and Trp53bp1−/−/Atm−/− cells, respectively; Table S6).
Consistent with the increased number of chromosomal breaks, we also observed an increase in the number of translocations in α-CD40/IL-4-activated double mutants (0.4, 1.0, 1.7 and 2.4 translocated ends per cell for wt, Trp53bp1−/−, Atm−/− and Trp53bp1−/−/Atm−/− metaphases, respectively; Table 2). Similar observations were made for LPS-activated B cells (Table 2). Finally, the greater number of breaks and translocations in double mutants was likely due to their defect in repair per se, because the marked G2/M checkpoint defect observed in Atm−/− cells was not modulated by 53BP1 status (Fig. S11).
Table 2.
Genotype | Cytokine | # metaphases analyzed | # broken ends analyzed | #translocated ends/ #nontranslocated ends | %trasnlocated ends/%nontranslocated ends | # breaks per cell/# translocated breaks per cell | ratio translocated/nontranslocated |
---|---|---|---|---|---|---|---|
wt | α-CD40/IL-4 | 90 | 91 | 37/54 | 40.7/59.3 | 1.0/0.4 | 0.7 |
Trp53bp1−/− | α-CD40/IL-4 | 90 | 301 | 93/208 | 30.9/69.1 | 3.3/1.0 | 0.4 |
Atm−/− | α-CD40/IL-4 | 90 | 471 | 150/321 | 31.8/68.2 | 5.2/1.7 | 0.5 |
Trp53bp1−/−/Atm−/− | α-CD40/IL-4 | 90 | 741 | 220/521 | 29.7/70.3 | 8.2/2.4 | 0.4 |
| |||||||
wt | LPS | 90 | 82 | 33/49 | 40.2/59.8 | 0.9/0.4 | 0.7 |
Trp53bp1−/− | LPS | 90 | 207 | 44/163 | 21.3/78.7 | 2.3/0.5 | 0.3 |
Atm−/− | LPS | 90 | 332 | 99/233 | 29.8/70.2 | 3.7/1.1 | 0.4 |
Trp53bp1−/−/Atm−/− | LPS | 90 | 392 | 121/271 | 30.9/69.1 | 4.4/1.3 | 0.4 |
53BP1 is dispensable for hybrid joint (HJ) formation, but suppresses large deletions at HJs
ATM suppresses the incorrect utilization of DNA ends during DSB repair (43). HJs are an aberrant product of V(D)J recombination, formed by the joining of a coding end to the signal end derived from the other participating gene segment. Consistent with its role in guiding appropriate end joining, ATM suppresses HJ formation (31). The role of 53BP1 in enforcing correct end utilization or in protecting DNA ends during short-range V(D)J recombination has not been addressed. We therefore assayed thymocytes from Atm−/− and Trp53bp1−/− mice for the presence of HJs as a measure of incorrect end utilization and examined the sequences of HJs for evidence of aberrant end processing and repair. Endogenous Dβ2-Vβ14 HJs were amplified from thymus DNA of 7 day-old wt, Trp53bp1−/−, Atm−/− and Trp53bp1−/−/Atm−/− mice (n=6 independent sets). Amplicons were detected by Southern hybridization to a radiolabeled, locus-specific probe (Fig. 5A). As expected, HJs were rare in wt thymocytes but readily detectable in Atm−/− cells (Fig. 5B, Fig. S12). In contrast, no or weak hybridization signals were observed in Trp53bp1−/− cells, indicating that, unlike ATM, 53BP1 does not function to suppress HJ formation.
Because previous work demonstrated that HJ formation in Atm−/− thymocytes is fully dependent on canonical NHEJ (44), we next asked whether 53BP1 is necessary for HJ formation in the absence of ATM. HJs were detected at similar amounts in Trp53bp1−/−/Atm−/− and Atm−/− controls (Fig. 5B, Fig. S12A), suggesting that 53BP1 is dispensable for NHEJ-dependent repair in this context. However, while a single band of the expected size was observed in Atm−/− DNA, we consistently detected one or several additional lower molecular weight bands in Trp53bp1−/−/Atm−/− samples (Fig. 5B and S12A). Sequencing of gel-extracted, high-mobility bands confirmed the deletions (Fig. 5C–D, Fig. S12B–C), consistent with the interpretation that 53BP1 functions to protect a subset of DNA ends from extensive end-resection prior to HJ formation. Sequence analysis enabled us to distinguish independent events on the basis of differential N-region insertion. Incidentally, deletion endpoints appeared to cluster at two sites within the Dβ2 signal flank, residing 267 – 268 and 347 – 348 bp from the signal end (Fig. 5D). Moreover, an apparent bias toward deletion from the signal end was observed when recombinants were amplified with primers placed at similar distances from the coding or signal ends (Fig. S12B–C). Taken together, these observations indicate that, in the context of HJ formation in ATM-deficient cells, removal of 53BP1 does not affect the frequency of incorrect end utilization, but rather markedly increases the extent of end resection that accompanies the joining of a subset of incorrect ends.
Discussion
53BP1 is being increasingly recognized as a tumor suppressor in a wide range of human cancers (13–18). Significantly, its functions in NHEJ-mediated repair were previously reported to be epistatic with those of ATM (20), consistent with their mutual regulation (7, 20–24). Here, we find that their functional interaction in NHEJ is context-dependent. In this regard, we observe epistasis during organismal growth and development and in the suppression of spontaneous genomic instability. In contrast, we find that 53BP1 becomes limiting for NHEJ-mediated repair after IR or during oncogenic stress, when the load of DSBs per cell is greater. Importantly, this work demonstrates that, in the pro-oncogenic environment generated by ATM deficiency, even a modest aggravation of the NHEJ defect in the absence of 53BP1 may have a profound clinical effect. This observation is in keeping with a recent report that 53BP1 deficiency similarly cooperates with oncogenic stress associated with AID overexpression to suppress B cell lymphomagenesis (45).
The clonal RAG-dependent translocations that drive Atm−/− tumors are normally suppressed by NHEJ (31). We propose that the accelerated acquisition of these translocations in double mutants is a direct result of their greater defect in NHEJ. Although the number of TCRα/δ breaks detected by cytogenetics in Atm−/− and Trp53bp1−/−/Atm−/− primary cells was too low for a direct comparison (our unpublished observations), we find that NHEJ-mediated repair in irradiated G1 splenocytes and thymocytes is consistently delayed in double mutants. When coupled with the severe checkpoint defects documented here, this deficiency alone could be sufficient to explain our observations in cycling cells, including: (1) increased numbers of γ-H2AX foci in G2; (2) increased polyploidy; and (3) increased chromosomal breaks and translocations in mitotic chromosomes. Our findings differ from those of a previous study which concluded that 53BP1 and ATM are fully epistatic in the repair of IR-induced DSB induced in G1 (20). This apparent discrepancy may reflect differences in methodologies, including but not limited to differential radiation dose and our use of ATM null cells rather than a chemical inhibitor of ATM.
Most relevant to our translocation-driven tumor model, we find a net increase in the formation of “random” chromosomal translocations in primary double mutant cells relative to single mutants. Although 53BP1 is required for the fusion of uncapped telomeres (9) and intra-chromosomal recombination (8, 46), 53BP1-deficient cells can nevertheless form intra- and inter-chromosomal rearrangements robustly (8, 45). In agreement with this notion, we find that approximately 30% of IR-induced chromosomal breaks are rearranged in 53BP1-deficient cells, regardless of ATM status. Intriguingly, the percentage of DNA ends undergoing translocation was higher (about 40%) in irradiated wild-type cells, despite the fact that they harbored fewer total breaks per cell and consequently fewer translocation “acceptors”. These observations suggest a model in which 53BP1 and ATM may play dual roles in the context of translocations. In this model they would primarily function to suppress translocations by promoting appropriate rejoining of DSBs. However, if repair fails and DNA ends are dissociated, 53BP1 and/or ATM would promote “aberrant” repair to form translocations, perhaps by helping bring the ends together and/or promoting the recruitment of classical or alternative NHEJ factors (9, 24). The observed translocation frequency would then reflect the balance between their anti- and pro-translocation activities, a notion that will be further examined in future work.
Mechanistically, 53BP1 promotes NHEJ by suppressing inappropriate DNA end-resection (6–8, 23, 45, 47, 48), preventing large deletions and/or use of highly error-prone pathways (35). Previous work has shown that ATM regulates end-resection in 53BP1-deficient cells in a cell cycle-dependent manner (47). Specifically, ATM suppressed end-resection in 53BP1-deficient cells in G1, but not in S/G2 (6, 7). Consistent with these findings, we report here increased deletions in a subset of RAG-mediated HJs in 53BP1-deficient thymocytes also lacking ATM. Together with previous observations (6, 7), this finding suggests that formation of at least a subset of HJs (and possibly chromosomal translocations) may require cell cycle progression. However, our finding that sequences at coding, signal and hybrid joints in double mutants are consistent with ligase IV-dependent canonical NHEJ suggests that this may be nevertheless the main pathway mediating HJs and chromosomal translocations, a notion that will be further examined in future work.
Finally, this work has important implications for our understanding of cancers harboring genetic alterations in DDR factors. Given that mutations in ATM are common in human cancers, it will be interesting to determine whether they are non-mutually exclusive with 53BP1 mutations, and to define their interplay in the natural history of disease and the response to therapy.
Supplementary Material
Acknowledgments
Financial support: Sonia Franco was supported by Research Scholar Grant RSG-12-160-01-DMC from the American Cancer Society. Stephen Desiderio was supported by grants CA016519 and CA160256 from the National Cancer Institute and by a gift to the Institute for Cell Engineering.
Footnotes
Conflict of interest statement: The authors declare no conflict of interest
References
- 1.Harper JW, Elledge SJ. The DNA damage response: ten years after. Molecular cell. 2007;28:739–45. doi: 10.1016/j.molcel.2007.11.015. [DOI] [PubMed] [Google Scholar]
- 2.Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–8. doi: 10.1038/nature08467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160–6. doi: 10.1126/science.1140321. [DOI] [PubMed] [Google Scholar]
- 4.Al-Hakim A, Escribano-Diaz C, Landry MC, O’Donnell L, Panier S, Szilard RK, et al. The ubiquitous role of ubiquitin in the DNA damage response. DNA repair. 2010;9:1229–40. doi: 10.1016/j.dnarep.2010.09.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Noon AT, Goodarzi AA. 53BP1-mediated DNA double strand break repair: Insert bad pun here. DNA repair. 2011;10:1071–6. doi: 10.1016/j.dnarep.2011.07.012. [DOI] [PubMed] [Google Scholar]
- 6.Bothmer A, Robbiani DF, Feldhahn N, Gazumyan A, Nussenzweig A, Nussenzweig MC. 53BP1 regulates DNA resection and the choice between classical and alternative end joining during class switch recombination. The Journal of experimental medicine. 2010;207:855–65. doi: 10.1084/jem.20100244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010;141:243–54. doi: 10.1016/j.cell.2010.03.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Difilippantonio S, Gapud E, Wong N, Huang CY, Mahowald G, Chen HT, et al. 53BP1 facilitates long-range DNA end-joining during V(D)J recombination. Nature. 2008;456:529–33. doi: 10.1038/nature07476. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Dimitrova N, Chen YC, Spector DL, de Lange T. 53BP1 promotes non-homologous end joining of telomeres by increasing chromatin mobility. Nature. 2008 doi: 10.1038/nature07433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352–5. doi: 10.1126/science.1140735. [DOI] [PubMed] [Google Scholar]
- 11.Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 2008;9:759–69. doi: 10.1038/nrm2514. [DOI] [PubMed] [Google Scholar]
- 12.Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S, et al. Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 doi: 10.1200/JCO.2011.41.0852. [DOI] [PubMed] [Google Scholar]
- 13.Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature structural & molecular biology. 2010;17:688–95. doi: 10.1038/nsmb.1831. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Li X, Xu B, Moran MS, Zhao Y, Su P, Haffty BG, et al. 53BP1 functions as a tumor suppressor in breast cancer via the inhibition of NF-kappaB through miR-146a. Carcinogenesis. 2012;33:2593–600. doi: 10.1093/carcin/bgs298. [DOI] [PubMed] [Google Scholar]
- 15.Neboori HJ, Haffty BG, Wu H, Yang Q, Aly A, Goyal S, et al. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. International journal of radiation oncology, biology, physics. 2012;83:e677–83. doi: 10.1016/j.ijrobp.2012.01.089. [DOI] [PubMed] [Google Scholar]
- 16.Squatrito M, Vanoli F, Schultz N, Jasin M, Holland EC. 53BP1 Is a Haploinsufficient Tumor Suppressor and Protects Cells from Radiation Response in Glioma. Cancer research. 2012;72:5250–60. doi: 10.1158/0008-5472.CAN-12-0045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Takeyama K, Monti S, Manis JP, Dal Cin P, Getz G, Beroukhim R, et al. Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas. Oncogene. 2008;27:318–22. doi: 10.1038/sj.onc.1210650. [DOI] [PubMed] [Google Scholar]
- 18.Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer discovery. 2013;3:68–81. doi: 10.1158/2159-8290.CD-12-0049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Lee JH, Goodarzi AA, Jeggo PA, Paull TT. 53BP1 promotes ATM activity through direct interactions with the MRN complex. The EMBO journal. 2010;29:574–85. doi: 10.1038/emboj.2009.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Noon AT, Shibata A, Rief N, Lobrich M, Stewart GS, Jeggo PA, et al. 53BP1-dependent robust localized KAP-1 phosphorylation is essential for heterochromatic DNA double-strand break repair. Nature cell biology. 2010;12:177–84. doi: 10.1038/ncb2017. [DOI] [PubMed] [Google Scholar]
- 21.Chapman JR, Barral P, Vannier JB, Borel V, Steger M, Tomas-Loba A, et al. RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection. Molecular cell. 2013 doi: 10.1016/j.molcel.2013.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Escribano-Diaz C, Orthwein A, Fradet-Turcotte A, Xing M, Young JT, Tkac J, et al. A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice. Molecular cell. 2013 doi: 10.1016/j.molcel.2013.01.001. [DOI] [PubMed] [Google Scholar]
- 23.Di Virgilio M, Callen E, Yamane A, Zhang W, Jankovic M, Gitlin AD, et al. Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching. Science. 2013 doi: 10.1126/science.1230624. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Zimmermann M, Lottersberger F, Buonomo SB, Sfeir A, de Lange T. 53BP1 Regulates DSB Repair Using Rif1 to Control 5′ End Resection. Science. 2013 doi: 10.1126/science.1231573. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Feng L, Fong KW, Wang J, Wang W, Chen J. RIF1 Counteracts BRCA1-mediated End Resection during DNA Repair. The Journal of biological chemistry. 2013;288:11135–43. doi: 10.1074/jbc.M113.457440. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Ward IM, Minn K, van Deursen J, Chen J. p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Molecular and cellular biology. 2003;23:2556–63. doi: 10.1128/MCB.23.7.2556-2563.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Borghesani PR, Alt FW, Bottaro A, Davidson L, Aksoy S, Rathbun GA, et al. Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:3336–41. doi: 10.1073/pnas.050584897. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Orsburn B, Escudero B, Prakash M, Gesheva S, Liu G, Huso DL, et al. Differential requirement for H2AX and 53BP1 in organismal development and genome maintenance in the absence of poly(ADP)ribosyl polymerase 1. Molecular and cellular biology. 2010;30:2341–52. doi: 10.1128/MCB.00091-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Rybanska I, Ishaq O, Chou J, Prakash M, Bakhsheshian J, Huso DL, et al. PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis. Oncogene. 2012 doi: 10.1038/onc.2012.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Zhang L, Reynolds TL, Shan X, Desiderio S. Coupling of v(d)j recombination to the cell cycle suppresses genomic instability and lymphoid tumorigenesis. Immunity. 2011;34:163–74. doi: 10.1016/j.immuni.2011.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Bredemeyer AL, Sharma GG, Huang CY, Helmink BA, Walker LM, Khor KC, et al. ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. Nature. 2006;442:466–70. doi: 10.1038/nature04866. [DOI] [PubMed] [Google Scholar]
- 32.Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nature cell biology. 2006;8:37–45. doi: 10.1038/ncb1337. [DOI] [PubMed] [Google Scholar]
- 33.Liyanage M, Weaver Z, Barlow C, Coleman A, Pankratz DG, Anderson S, et al. Abnormal rearrangement within the alpha/delta T-cell receptor locus in lymphomas from Atm-deficient mice. Blood. 2000;96:1940–6. [PubMed] [Google Scholar]
- 34.Zha S, Bassing CH, Sanda T, Brush JW, Patel H, Goff PH, et al. ATM-deficient thymic lymphoma is associated with aberrant tcrd rearrangement and gene amplification. The Journal of experimental medicine. 2010;207:1369–80. doi: 10.1084/jem.20100285. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Symington LS, Gautier J. Double-strand break end resection and repair pathway choice. Annual review of genetics. 2011;45:247–71. doi: 10.1146/annurev-genet-110410-132435. [DOI] [PubMed] [Google Scholar]
- 36.Marculescu R, Vanura K, Montpellier B, Roulland S, Le T, Navarro JM, et al. Recombinase, chromosomal translocations and lymphoid neoplasia: targeting mistakes and repair failures. DNA repair. 2006;5:1246–58. doi: 10.1016/j.dnarep.2006.05.015. [DOI] [PubMed] [Google Scholar]
- 37.Callen E, Jankovic M, Difilippantonio S, Daniel JA, Chen HT, Celeste A, et al. ATM prevents the persistence and propagation of chromosome breaks in lymphocytes. Cell. 2007;130:63–75. doi: 10.1016/j.cell.2007.06.016. [DOI] [PubMed] [Google Scholar]
- 38.Callen E, Jankovic M, Wong N, Zha S, Chen HT, Difilippantonio S, et al. Essential role for DNA-PKcs in DNA double-strand break repair and apoptosis in ATM-deficient lymphocytes. Molecular cell. 2009;34:285–97. doi: 10.1016/j.molcel.2009.04.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Franco S, Murphy MM, Li G, Borjeson T, Boboila C, Alt FW. DNA-PKcs and Artemis function in the end-joining phase of immunoglobulin heavy chain class switch recombination. The Journal of experimental medicine. 2008;205:557–64. doi: 10.1084/jem.20080044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nature reviews Genetics. 2012;13:189–203. doi: 10.1038/nrg3123. [DOI] [PubMed] [Google Scholar]
- 41.Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010;116:4578–87. doi: 10.1182/blood-2010-01-265769. [DOI] [PubMed] [Google Scholar]
- 42.Franco S, Gostissa M, Zha S, Lombard DB, Murphy MM, Zarrin AA, et al. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Molecular cell. 2006;21:201–14. doi: 10.1016/j.molcel.2006.01.005. [DOI] [PubMed] [Google Scholar]
- 43.Bennardo N, Stark JM. ATM limits incorrect end utilization during non-homologous end joining of multiple chromosome breaks. PLoS genetics. 2010;6:e1001194. doi: 10.1371/journal.pgen.1001194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Bredemeyer AL, Huang CY, Walker LM, Bassing CH, Sleckman BP. Aberrant V(D)J recombination in ataxia telangiectasia mutated-deficient lymphocytes is dependent on nonhomologous DNA end joining. J Immunol. 2008;181:2620–5. doi: 10.4049/jimmunol.181.4.2620. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Jankovic M, Feldhahn N, Oliveira TY, Silva IT, Kieffer-Kwon KR, Yamane A, et al. 53BP1 Alters the Landscape of DNA Rearrangements and Suppresses AID-Induced B Cell Lymphoma. Molecular cell. 2013 doi: 10.1016/j.molcel.2012.11.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Bothmer A, Robbiani DF, Di Virgilio M, Bunting SF, Klein IA, Feldhahn N, et al. Regulation of DNA End Joining, Resection, and Immunoglobulin Class Switch Recombination by 53BP1. Molecular cell. 2011;42:319–29. doi: 10.1016/j.molcel.2011.03.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Yamane A, Robbiani DF, Resch W, Bothmer A, Nakahashi H, Oliveira T, et al. RPA Accumulation during Class Switch Recombination Represents 5′-3′ DNA-End Resection during the S-G2/M Phase of the Cell Cycle. Cell reports. 2013 doi: 10.1016/j.celrep.2012.12.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Sfeir A, de Lange T. Removal of shelterin reveals the telomere end-protection problem. Science. 2012;336:593–7. doi: 10.1126/science.1218498. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.